Specifically, the risk of requiring insulin treatment after gallbladder and pancreatic cancer development was higher in the first year after cancer diagnosis, whereas hematologic cancer showed a relatively lower risk of requiring insulin treatment after cancer development during the three years (Figure 4). Here, INS is linked to hematopoietic and lymphoid cell neoplasm.